Mizuno Keiko, Mataki Hiroko, Seki Naohiko, Kumamoto Tomohiro, Kamikawaji Kazuto, Inoue Hiromasa
Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
J Hum Genet. 2017 Jan;62(1):57-65. doi: 10.1038/jhg.2016.98. Epub 2016 Aug 4.
In spite of advances in the diagnosis and current molecular target therapies of lung cancer, this disease remains the most common cause of cancer-related death worldwide. Approximately 80% of lung cancers is non-small cell lung cancer (NSCLC), and 5-year survival rate of the disease is ~20%. On the other hand, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology. IPF is refractory to treatment and has a very low survival rate. Moreover, IPF is frequently associated with lung cancer. However, the common mechanisms shared by these two diseases remain poorly understood. In the post-genome sequence era, the discovery of noncoding RNAs, particularly microRNAs (miRNAs), has had a major impact on most biomedical fields, and these small molecules have been shown to contribute to the pathogenesis of NSCLC and IPF. Investigation of novel RNA networks mediated by miRNAs has improved our understanding of the molecular mechanisms of these diseases. This review summarizes our current knowledge on aberrantly expressed miRNAs regulating NSCLC and IPF based on miRNA expression signatures.
尽管肺癌的诊断和当前分子靶向治疗取得了进展,但这种疾病仍然是全球癌症相关死亡的最常见原因。大约80%的肺癌是非小细胞肺癌(NSCLC),该疾病的5年生存率约为20%。另一方面,特发性肺纤维化(IPF)是一种病因不明的慢性、进行性间质性肺疾病。IPF治疗难治,生存率极低。此外,IPF常与肺癌相关。然而,这两种疾病共有的常见机制仍知之甚少。在后基因组序列时代,非编码RNA的发现,尤其是微小RNA(miRNA),对大多数生物医学领域产生了重大影响,并且这些小分子已被证明与NSCLC和IPF的发病机制有关。对由miRNA介导的新型RNA网络的研究增进了我们对这些疾病分子机制的理解。本综述基于miRNA表达特征总结了我们目前对调节NSCLC和IPF的异常表达miRNA的认识。